ATS Corporation (FRA:ATO0)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.41B -7.8% |
| Revenue (ttm) | 1.85B +17.4% |
| Net Income | 44.51M |
| EPS | 0.45 |
| Shares Out | n/a |
| PE Ratio | 54.19 |
| Forward PE | 20.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 24.60 |
| Previous Close | 24.60 |
| Day's Range | 24.60 - 24.60 |
| 52-Week Range | 20.80 - 30.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About ATS Corporation
ATS Corporation, together with its subsidiaries, engages in the planning, designing, building, commissioning, and servicing of automated manufacturing and assembly systems worldwide. The company offers pre-automation services comprising discovery and analysis, concept development, simulation, and total cost of ownership modeling; post-automation services, including training, process optimization, preventive maintenance, emergency and on-call support, spare parts, retooling, retrofits, and equipment relocation; and contract manufacturing service... [Read more]
News
Fusemachines Expands Access to Agentic AI for Talent Acquisition Through Broad ATS Connectivity
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Fusemachines Inc. (NASDAQ: FUSE), a leading provider of enterprise AI products and services, today announced expanded enterprise access to its Agentic AI fo...
New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 in...
Desjardins starts ATS Corporation with a Buy, cites high barriers to entry
As previously reported last night, Desjardins initiated coverage of ATS Corporation (ATS) with a Buy rating and C$52 price target ATS, which plans, designs, builds, commissions and services automated ...
ATS Corporation initiated with a Buy at Desjardins
Desjardins initiated coverage of ATS Corporation (ATS) with a Buy rating and C$52 price target
ATS to Participate in the Stifel Summer Solstice Conference
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Anne Cybulski, Interim Chief Financial Officer, will participate in the Stifel...
ATS Corporation Slides: Investor presentation
ATS Corporation has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
ATS Q4 Earnings Call Highlights
ATS NYSE: ATS reported higher fiscal 2026 revenue and adjusted earnings from operations, while outlining a series of restructuring actions aimed at improving margins, cash generation and capital effic...
ATS Corporation Earnings Call Transcript: Q4 2026
Revenue and adjusted earnings grew 11% year-over-year, with Q4 margins and cash flow improving. Fiscal 2027 guidance calls for modest revenue growth and 50-75 bps margin expansion, supported by a CAD 2B backlog and strong life sciences and energy segments.
ATS Corporation Slides: Q4 2026
ATS Corporation has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 28, 2026.
ATS Corporation Registration statement: Q4 2026
ATS Corporation filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
ATS Corporation Registration statement: Q4 2026
ATS Corporation filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
ATS Corporation Annual report: Q4 2026
ATS Corporation has published its Q4 2026 annual report on May 28, 2026.
ATS Corporation Earnings release: Q4 2026
ATS Corporation released its Q4 2026 earnings on May 28, 2026, summarizing the period's financial results.
ATS Corporation Earnings release: Q4 2026
ATS Corporation released its Q4 2026 earnings on May 28, 2026, summarizing the period's financial results.
ATS Corporation sees Q1 revenue $700M-$740M, consensus $758.64M
06:06 EDT ATS Corporation (ATS) sees Q1 revenue $700M-$740M, consensus $758.64M
ATS Corporation sees FY27 revenue growth “modest”, consensus $2.96B
Management believes that the underlying trends driving customer demand for ATS solutions, including growing labour constraints, production onshoring or reshoring and the need for scalable, high-qualit...
ATS Corporation reports Q4 adjusted EPS 36c, consensus 32c
Reports Q4 revenue $747.1M, consensus $732.14M. “Today ATS reported fourth quarter and full-year results for fiscal 2026, with full-year revenue and adjusted earnings from operations growth of approxi...
ATS Reports Fourth Quarter Fiscal 2026 Results
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and twelve months ended March 31, 2026. All referen...
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 Internati...
ATS to Host Fourth Quarter Earnings Call Thursday May 28, 2026, at 8:30 a.m. Eastern
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the fourth quarter ended March 31, 2026, before markets open ...
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyse...
ATS Corporation price target raised to C$51 from C$48 at Scotiabank
Scotiabank raised the firm’s price target on ATS Corporation (ATS) to C$51 from C$48 and keeps an Outperform rating on the shares.
ATS Corporation Registration statement: Registration filing
ATS Corporation filed a registration statement on April 27, 2026, providing details about a securities offering with the SEC.
ATS Corporation price target lowered to $30 from $31 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on ATS Corporation (ATS) to $30 from $31 and keeps a Sell rating on the shares. The firm is updating its models as